TNF-alpha inhibitors

All congenital malformations (majors, minors, majors and minors, or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S4958
R12999
De Lorenzo (Controls unexposed, disease free), 2020 Malformations at least 1st trimester retrospective cohort unexposed, disease free excluded Adjustment: No 7.00 [0.57;85.39] C
excluded (control group)
2/12   1/36 3 12
ref
S4959
R13005
De Lorenzo (Controls unexposed, sick), 2020 Malformations at least 1st trimester retrospective cohort unexposed, sick Adjustment: No 16.58 [0.73;376.16] C 2/12   0/32 2 12
ref
S4995
R13095
Drechsel, 2020 Major congenital malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 1.59 [0.06;41.24] C 0/14   1/66 1 14
ref
S4952
R12991
Moens (Controls exposed to Vedolizumab), 2020 Congenital anomalies (NOS) at least 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.51 [0.11;2.37] C
excluded (control group)
4/162   3/64 7 162
ref
S4951
R12986
Moens (Controls unexposed, sick), 2020 Congenital anomalies (NOS) at least 1st trimester retrospective cohort unexposed, sick Adjustment: No 1.35 [0.30;6.13] C 4/162   3/163 7 162
ref
S3072
R4708
Duricova, 2019 Congenital malformations during pregnancy (anytime or not specified) excluded retrospective cohort unexposed, disease free Adjustment: No 0.82 [0.28;2.40] C
excluded (exposition period)
7/72   8/69 15 72
ref
S4997
R13101
Fu - Etanercept, 2019 Congenital malformation (major or minor) 1st trimester randomized controlled trial unexposed, sick Adjustment: Randomisation 1.59 [0.14;17.92] C 2/85   1/67 3 85
ref
S3066
R4667
Chaparro, 2018 Congenital malformations (NOS) 3 months (or more) before pregnancy or during pregnancy excluded retrospective cohort unexposed, sick Adjustment: No before conception and/or during pregnancy 2.10 [1.02;4.33] C
excluded (exposition period)
21/388   12/453 33 388
ref
S3123
R11336
De Lima, 2018 Major congenital abnormalities at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 0.79 [0.01;43.11] C 0/15   0/12 0 15
ref
S3093
R4771
Luu, 2018 Malformations during pregnancy (anytime or not specified) excluded retrospective cohort (claims database) exposed to other treatment, sick Adjustment: No 0.98 [0.72;1.33] C
excluded (exposition period)
49/799   303/4,836 352 799
ref
S4098
R11330
Carman - Etanercept (Controls unexposed, disease free), 2017 Major malformations during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, disease free excluded Adjustment: No 0.95 [0.49;1.85] C
excluded (control group)
11/210   59/1,078 70 210
ref
S4099
R11331
Carman - Etanercept (Controls unexposed, sick), 2017 Major malformations during pregnancy (anytime or not specified) excluded retrospective cohort (claims database) unexposed, sick Adjustment: No 1.08 [0.57;2.05] C
excluded (exposition period)
11/210   94/1,932 105 210
ref
S4106
R11333
Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 Major birth defects among all pregnancies at least 1st trimester prospective cohort unexposed, sick Adjustment: Yes 0.91 [0.37;2.23] -/-   -/- - -
ref
S3009
R11339
Hoxha, 2017 Congenital malformation 1st trimester prospective cohort unexposed, sick Adjustment: No 0.43 [0.02;7.66] C 1/24   1/11 2 24
ref
S3194
R11328
Bröms a (Controls unexposed, disease free), 2016 Any major birth defect 3 months or more before pregnancy or1st trimester population based cohort retrospective unexposed, disease free excluded Adjustment: No 1.53 [1.12;2.08] C
excluded (control group)
43/683   52,592/1,250,192 52,635 683
ref
S3193
R11329
Bröms a (Controls unexposed, sick), 2016 Any major birth defect 3 months or more before pregnancy or1st trimester excluded population based cohort retrospective unexposed, sick Adjustment: Yes 1.32 [0.93;1.82]
excluded (exposition period)
43/683   1,019/21,549 1,062 683
ref
S3070
R4688
De Lima (Controls unexposed, disease free), 2016 Congenital Abnormalities 1st and 2nd trimester prospective cohort unexposed, disease free Adjustment: No 1.04 [0.31;3.49] C 3/83   28/804 31 83
ref
S3069
R4679
Agosti, 2015 Congenital malformations (severe or not) during pregnancy (anytime or not specified) excluded retrospective cohort unexposed, sick Adjustment: No 1.00 [0.18;5.53] C
excluded (exposition period)
3/24   3/24 6 24
ref
S4104
R11334
Chambers - Etanercept, 2015 Major birth defects in live born infants at least 1st trimester prospective cohort unexposed, sick Adjustment: Yes 2.77 [1.04;7.35] -/-   -/- - -
ref
S2888
R4104
Weber-Schoendorfer, 2015 All birth defects 1st trimester prospective cohort unexposed, disease free Adjustment: Yes 1.64 [1.10;2.60] 52/423   87/1,393 139 423
ref
S4074
R11335
Cooper, 2014 Major congenital malformations 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: Yes 1.59 [0.30;8.47] 2/56   4/171 6 56
ref
S2897
R11337
Diav-Citrin (Controls exposed to other treatments), 2014 Major malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.72 [0.16;3.12] C
excluded (control group)
3/65   5/79 8 65
ref
S2893
R11338
Diav-Citrin (Controls unexposed, disease free), 2014 Major malformations 1st trimester prospective cohort unexposed, disease free Adjustment: No 1.98 [0.51;7.69] C 3/65   8/336 11 65
ref
S3037
R4576
Seirafi, 2014 Congenital malformations 3 months (or more) before pregnancy or during pregnancy excluded retrospective cohort unexposed, sick Adjustment: No before conception and/or during pregnancy 0.25 [0.03;2.42] C
excluded (exposition period)
1/118   3/90 4 118
ref
S3014
R11332
Casanova, 2013 Congenital malformations (NOS) 3 months (or more) before pregnancy or during pregnancy excluded retrospective cohort exposed to other treatment, sick Adjustment: No 4.58 [0.28;74.22] C
excluded (exposition period)
1/60   1/271 2 60
ref
S13730
R53470
Viktil (Controls exposed to other treatments), 2012 Major malformations 3 months or more before pregnancy or1st trimester population based cohort propective exposed to other treatment, sick excluded Adjustment: No 0.34 [0.02;5.67] C
excluded (control group)
0/40   50/1,421 50 40
ref
S13731
R53472
Viktil (Controls unexposed, NOS), 2012 Major malformations 3 months or more before pregnancy or1st trimester excluded population based cohort propective unexposed (general population or NOS) Adjustment: No 0.38 [0.02;6.18] C
excluded (exposition period)
0/40   5,000/154,976 5,000 40
ref
S3017
R4524
Schnitzler (Controls unexposed, disease free), 2011 Malformations (NOS) 3 months (or more) before pregnancy or during pregnancy prospective cohort unexposed, disease free excluded Adjustment: No before conception and/or during pregnancy 4.11 [0.16;103.53] C
excluded (control group)
1/42   0/56 1 42
ref
S3018
R4523
Schnitzler (Unexposed control, sick), 2011 Malformations (NOS) 3 months (or more) before pregnancy or during pregnancy excluded prospective cohort unexposed, sick Adjustment: No before conception and/or during pregnancy 1.88 [0.11;30.81] C
excluded (exposition period)
1/42   1/78 2 42
ref
S2916
R13111
Verstappen, 2011 Congenital malformations early pregnancy prospective cohort unexposed, sick Adjustment: No 1.80 [0.24;13.44] C 2/32   2/56 4 32
ref
Total 13 studies 1.57 [1.16;2.14] 206 971
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF De Lorenzo (Controls unexposed, sick), 2020De Lorenzo, 2020 1 16.58[0.73; 376.16]2121%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Drechsel, 2020Drechsel, 2020 1.59[0.06; 41.24]1141%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Moens (Controls unexposed, sick), 2020Moens, 2020 2 1.35[0.30; 6.13]71624%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Fu - Etanercept, 2019Fu - Etanercept, 2019 1.59[0.14; 17.92]3852%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA De Lima, 2018De Lima, 2018 0.79[0.01; 43.11]0151%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017Chambers - Adalimumab, 2017 3 0.91[0.37; 2.23]--12%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Hoxha, 2017Hoxha, 2017 0.43[0.02; 7.66]2241%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA De Lima (Controls unexposed, disease free), 2016De Lima, 2016 4 1.04[0.31; 3.49]31836%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Chambers - Etanercept, 2015Chambers - Etanercept, 2015 2.77[1.04; 7.35]--10%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Weber-Schoendorfer, 2015Weber-Schoendorfer, 2015 1.64[1.10; 2.60]13942351%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Cooper, 2014Cooper, 2014 1.59[0.30; 8.47]6563%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Diav-Citrin (Controls unexposed, disease free), 2014Diav-Citrin, 2014 5 1.98[0.51; 7.69]11655%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Verstappen, 2011Verstappen, 2011 1.80[0.24; 13.44]4322%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (13 studies) I2 = 0% 1.57[1.16; 2.14]2069710.250.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick, ADA only; 4: Controls unexposed, disease free; 5: Controls unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.57[1.15; 2.15]2038860%NADe Lorenzo (Controls unexposed, sick), 2020 Drechsel, 2020 Moens (Controls unexposed, sick), 2020 De Lima, 2018 Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 Hoxha, 2017 De Lima (Controls unexposed, disease free), 2016 Chambers - Etanercept, 2015 Weber-Schoendorfer, 2015 Cooper, 2014 Diav-Citrin (Controls unexposed, disease free), 2014 Verstappen, 2011 12 case control studiescase control studies 0 RCTRCT 1.59[0.14; 17.92]385 -NAFu - Etanercept, 2019 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.59[1.08; 2.34]1815710%NADe Lima (Controls unexposed, disease free), 2016 Weber-Schoendorfer, 2015 Diav-Citrin (Controls unexposed, disease free), 2014 3 unexposed, sickunexposed, sick 1.56[0.94; 2.61]253850%NADe Lorenzo (Controls unexposed, sick), 2020 Drechsel, 2020 Moens (Controls unexposed, sick), 2020 Fu - Etanercept, 2019 Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 Hoxha, 2017 Chambers - Etanercept, 2015 Cooper, 2014 Verstappen, 2011 9 exposed to other treatment, sickexposed to other treatment, sick 0.79[0.01; 43.11]-15 -NADe Lima, 2018 1 Tags Adjustment   - No  - No 1.48[0.76; 2.86]584070%NADe Lorenzo (Controls unexposed, sick), 2020 Drechsel, 2020 Moens (Controls unexposed, sick), 2020 De Lima, 2018 Hoxha, 2017 De Lima (Controls unexposed, disease free), 2016 Diav-Citrin (Controls unexposed, disease free), 2014 Verstappen, 2011 8   - Randomisation  - Randomisation 1.59[0.14; 17.92]385 -NAFu - Etanercept, 2019 1   - Yes  - Yes 1.60[1.13; 2.28]1454790%NAChambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 Chambers - Etanercept, 2015 Weber-Schoendorfer, 2015 Cooper, 2014 4 All studiesAll studies 1.57[1.16; 2.14]2069710%NADe Lorenzo (Controls unexposed, sick), 2020 Drechsel, 2020 Moens (Controls unexposed, sick), 2020 Fu - Etanercept, 2019 De Lima, 2018 Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 Hoxha, 2017 De Lima (Controls unexposed, disease free), 2016 Chambers - Etanercept, 2015 Weber-Schoendorfer, 2015 Cooper, 2014 Diav-Citrin (Controls unexposed, disease free), 2014 Verstappen, 2011 130.250.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.85.22.4460.000De Lorenzo (Controls unexposed, sick), 2020Drechsel, 2020Moens (Controls unexposed, sick), 2020Fu - Etanercept, 2019De Lima, 2018Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017Hoxha, 2017De Lima (Controls unexposed, disease free), 2016Chambers - Etanercept, 2015Weber-Schoendorfer, 2015Cooper, 2014Diav-Citrin (Controls unexposed, disease free), 2014Verstappen, 2011

Asymetry test p-value = 0.9888 (by Egger's regression)

slope=0.4506 (0.2033); intercept=0.0051 (0.3584); t=0.0144; p=0.9888

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 3017, 13730, 2897, 3194, 4098, 4958, 4952

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.65[1.12; 2.42]1845830%NADe Lorenzo (Controls unexposed, disease free), 2020 De Lima (Controls unexposed, disease free), 2016 Weber-Schoendorfer, 2015 Diav-Citrin (Controls unexposed, disease free), 2014 4 unexposed, sick controlsunexposed, sick controls 1.56[0.94; 2.61]253850%NADe Lorenzo (Controls unexposed, sick), 2020 Drechsel, 2020 Moens (Controls unexposed, sick), 2020 Fu - Etanercept, 2019 Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 Hoxha, 2017 Chambers - Etanercept, 2015 Cooper, 2014 Verstappen, 2011 9 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.62[0.22; 1.73]152420%NAMoens (Controls exposed to Vedolizumab), 2020 De Lima, 2018 Diav-Citrin (Controls exposed to other treatments), 2014 30.510.01.0